Last reviewed · How we verify
NCT04920149: MesaCAPP
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Phase 2 trial testing Mesalamine in Lynch Syndrome in 150 participants. Currently enrolling.
30 September 2032
Quick facts
| Lead sponsor | Ann-Sofie Backman |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 150 |
| Start date | 21 March 2022 |
| Primary completion | 30 September 2032 |
| Estimated completion | 30 September 2045 |
| Sites | 8 locations across Denmark, Sweden |
Drugs / interventions tested
- Mesalamine — full drug profile →
- Placebo
Conditions studied
- Lynch Syndrome — all drugs for Lynch Syndrome →
- Colon Cancer — all drugs for Colon Cancer →
- Colon Neoplasm — all drugs for Colon Neoplasm →
Sponsor
Ann-Sofie Backman
Who can join
30 and older, any sex, with Lynch Syndrome or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer.
Słoka J, Madej M, Strzalka-Mrozik B. · · 2023 · cited 25× · PMID 37446747 · DOI 10.3390/molecules28135081 -
Personalized Systemic Therapies in Hereditary Cancer Syndromes.
Mastrodomenico L, Piombino C, Riccò B, Barbieri E, et al · · 2023 · cited 9× · PMID 36980956 · DOI 10.3390/genes14030684 -
Influence of Mesalazine on Ferroptosis-Related Gene Expression in In Vitro Colorectal Cancer Culture.
Słoka J, Strzałka-Mrozik B, Kubica S, Nowak I, et al · · 2025 · cited 4× · PMID 39857803 · DOI 10.3390/biomedicines13010219 -
Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.
Backman AS, Frank A, Lindberg LJ, Ljungman D, et al · · 2025 · PMID 41213710 · DOI 10.1136/bmjopen-2025-100082
Verify or expand the search:
- PubMed search for NCT04920149
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mesalamine
Trials testing the same drug.
- NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
- NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
- NCT07064707 — Rupatadine in Patients With Ulcerative Colitis · Phase 2 · recruiting
- NCT06993974 — Nitazoxanide in Patients With Ulcerative Colitis · Phase 2 · recruiting
- NCT06525974 — Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated Wi · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Lynch Syndrome
Currently open trials in the same condition.
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT06582914 — Lynch Syndrome Integrative Epidemiology and Genetics · recruiting
- NCT06447961 — PSYLIVED: the Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition Syndrome · recruiting
- NCT05963191 — CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome · NA · recruiting
- NCT06712095 — Video Capsule Examination in Patients With Lynch Syndrome · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04920149 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ann-Sofie Backman
- Last refreshed: 17 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920149.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing